Zealand Pharma A/S (ZLDPF) shares ended the last trading session 8% higher at $72.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.3% loss over the past four weeks.

Last month, the company announced that it has enrolled the first participant in the phase IIb ZUPREME-2 study. This study evaluates the efficacy and safety of petrelintide versus placebo in people with obesity and type 2 diabetes. Enrollment in the ZUPREME-2 study is expected to be completed in the second half of 2025. The growing optimism related to the development of petrelintide might have driven the recent share price rally.

This company is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -42.6%. Revenues are expected to be $3.81 million, up 73.2% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Zealand Pharma AS, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZLDPF going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Zealand Pharma AS belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Akoya Biosciences (AKYA), closed the last trading session 5.5% lower at $1.20. Over the past month, AKYA has returned -5.9%.

For Akoya , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.29. This represents a change of +17.1% from what the company reported a year ago. Akoya currently has a Zacks Rank of #4 (Sell).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zealand Pharma A/S (ZLDPF):Free Stock Analysis Report

Akoya Biosciences, Inc. (AKYA):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments